| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.04. | One-carbon Therapeutics collaborates with Tempus in cancer treatment | ||
| 10.04. | Lilly to acquire Centessa in deal worth up to $7.8bn | ||
| 10.04. | Takeda's CEO-elect, Julie Kim, proposed as new candidate for Board of Directors | ||
| 09.04. | Biogen to acquire Apellis in $5.6bn deal | ||
| 09.04. | Matt Ferriday announced as General Manager for LEO Pharma UK | ||
| 08.04. | Gilead to acquire Tubulis for up to $5bn | ||
| 08.04. | Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development | ||
| 07.04. | Lilly's Foundayo approved by US FDA as oral GLP-1 for weight loss | ||
| 07.04. | Marking World Health Day on 7 April | ||
| 02.04. | Roche opens new Swiss Institute of Human Biology research facility | ||
| 02.04. | ReproNovo appoints Mark Altmeyer as Chairman of the Board | ||
| 01.04. | Novartis to acquire Excellergy in deal worth up to $2bn | ||
| 01.04. | Poolbeg Pharma appoints Adrian Kilcoyne to Scientific Advisory Board | ||
| 31.03. | Pharma's content paradox: why more content is not the answer | ||
| 31.03. | Achieving comms excellence through personalised engagement | ||
| 31.03. | Novo Nordisk's Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes | ||
| 31.03. | Sandoz partners with Samsung Bioepis to develop up to five biosimilars | ||
| 30.03. | The digital age and the advance of AI - pushing communications to new heights | ||
| 30.03. | Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment | ||
| 30.03. | Ipsen appoints Michelle Werner as Executive Vice President, President of North America | ||
| 27.03. | Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development | ||
| 27.03. | PM Society Board welcomes Frankie Everson and Mark Wheeler | ||
| 26.03. | BMS' Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma | ||
| 26.03. | BOOST Pharma appoints Elaine Jones as Board Chair | ||
| 25.03. | Eisai and Biogen's new data shows Alzheimer's patients choose to stay on Leqembi long-term |